Research programme: aldosterone synthase inhibitors - ElexoPharm/Merck

Drug Profile

Research programme: aldosterone synthase inhibitors - ElexoPharm/Merck

Alternative Names: Aldosterone synthase cytochrome P-450 inhibitors; CYP11B2 inhibitors - ElexoPharm; Cytochrome P-450 CYP11B2 inhibitors - ElexoPharm

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ElexoPharm GmbH
  • Developer Angion Biomedica; ElexoPharm GmbH; Merck & Co
  • Class Cardiovascular therapies
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Kidney disorders
  • No development reported Cardiovascular disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Germany
  • 22 Jun 2017 Early research in Kidney disorders in USA (unspecified route)
  • 22 Jun 2017 Angion Biomedica in-licensed aldosterone synthase inhibitors from ElexoPharm GmbH for the treatment of chronic kidney disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top